HI PRIX (Health Innovation Next Generation Payment and Pricing Models)

Research areas: European collaboration, HTA-methods & steering instruments

Project lead: Claudia Wild
Duration: January 2023 – December 2025

HI-PRIX - Health innovation next generation payment & pricing models (hiprixhorizon.eu)

Publication: HTA Project Report No. 158: https://eprints.aihta.at/1499/

The variety of novel technologies with the potential to improve the delivery of health care means that the policy toolbox will need more pricing and payment models, adapted in their design and implementation according to the specific situation. Although there are examples of novel pricing and payment models, the lack of appropriate data infrastructure, legal barriers and unwillingness to adapt current systems often prevent their use. Therefore, the overall objectives of the Health Innovation Next Generation Pricing Models (HI – PRIX) project are:

1. to map and formulate new pricing and payment schemes that can be used across technology classes, therapeutic areas, setting and healthcare systems/geographies together with a related set of principles that may guide successful adjustment and flexible implementation to the context of use;
2. to investigate the impact on competitiveness, innovation, equity and affordability of a pipeline of contracting modalities for health innovations;
3. to address the challenges and concerns of payers, manufacturers, healthcare professionals, and patients about different models of pricing by sustaining an effective dialogue across stakeholders’ groups about the trade-offs between affordability, innovation and patient access.

Coordinated by Bocconi University, the HI-PRIX Consortium involves 18 partners from 10 European countries, including academic institutions, public authorities, healthcare providers, and independent research organizations. Through theoretical models, quantitative simulation, qualitative research work and case-studies, this three-year project structured around 10 WPs, will generate new evidence on the role of public sector in R&D and indirect medical and environmental costs in pricing and reimbursement determinations, on the pricing

dynamics over pharmaceutical products’ lifecycle, on the impact of policies and incentives on the competitiveness, innovativeness and equity in the healthcare system.

The role of the AIHTA is to collect data and evidence on public expenditure in R&D and on beneficiaries.

HORIZON-HLTH-2022-IND-13-03 (RIA)